Kentucky
How Association for Molecular Pathology v. Myriad Genetics, Inc. applies in Kentucky: state-specific rules, key cases, and bar exam notes for Intellectual Property (Patent Law).
Kentucky courts follow federal patent law closely; however, state law may impact the enforcement and interpretation of patents related to genetics. The principles articulated in the Myriad case resonate in Kentucky, emphasizing the non-patentability of isolated DNA sequences.
In Kentucky, similar to federal law, currently isolated natural sequences are not patentable due to their lack of sufficient human intervention beyond identification and isolation.
The court held that isolated genes do not meet the criteria for patent eligibility as they are products of nature.
This case reinforced the notion that functional derivatives of natural products must demonstrate sufficient invention to be patentable.
The court clarified the scope of natural substances eligible for patent protection following the precedent set by Myriad.
Kentucky’s approach mirrors that of the federal standard established in Myriad, particularly concerning the non-patentability of isolated genetic material. However, unique state legislation could influence the application of these principles in specific cases.
Understanding the implications of Myriad on genetic patenting is crucial for the Kentucky bar exam, especially within the Intellectual Property section and when discussing patent eligibility.